Donald Trump's announcement of future 25% tariffs on various sectors, including the pharmaceutical industry, prompted the European Commission to revive the concept of strategic autonomy to boost competitiveness.

The Commission will today unveil its Critical Medicines Act (CMA), a plan to gain sovereignty in this sensitive and strategic area.